New inhaled TB drug shows promise in early trial
NCT ID NCT07073638
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new inhaled medicine called RESP30TB in 24 adults with newly diagnosed, drug-sensitive tuberculosis of the lungs. The main goals are to see if the drug is safe and how well it kills TB bacteria in the early days of treatment. Participants will inhale the drug and be closely monitored for side effects and sputum changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY TUBERCULOSES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
TASK Clinical Research Centre
RECRUITINGCape Town, Bellville, 7531, South Africa
More trials for these conditions
Other studies related to the condition(s) this trial covers.